Leerink Partners analyst Mani Foroohar reiterated a Buy rating on bluebird bio on Wednesday, setting a price target of $68, which is approximately 123.10% above the present share price of $30.48.
Foroohar expects bluebird bio to post earnings per share (EPS) of $0.00 for the second quarter of 2021.
The current consensus among 18 TipRanks analysts is for a Moderate Buy rating of shares in Bluebird Bio (NASDAQ:BLUE), with an average price target of $44.5.
The analysts price targets range from a high of $86 to a low of $27.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $12.79 million and a net profit of -$230.84 million. The company's market cap is $2.06 billion.
According to TipRanks.com, Leerink Partners analyst Mani Foroohar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -6.8% and a 40.91% success rate.
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.